Biopharmaceutical company, Secarna Pharmaceuticals, has entered into a co-development agreement with research and development company, Firebrand Therapeutics, for novel cancer therapies.
Cancer cell
As per the agreement, the companies will leverage Secarna’s LNAplus platform to pursue novel targets playing a key role in cancer metastasis, with Firebrand contributing its expertise in the field.
“This agreement is a significant milestone for Secarna as this co-development project will further validate our approach to develop highly specific, safety-optimised and efficacious antisense oligonucleotide therapies for challenging and previously undruggable targets,” commented Jonas Renz, managing director and co-founder of Secarna Pharmaceuticals. “Antisense oligonucleotides are gaining tremendous momentum following recent drug approvals. With our third generation LNAplus platform, I believe we are on our way to write new chapters in the book of antisense oligonucleotide discovery and development.”
Financial terms of the agreement were not disclosed.